Abstract: The invention relates to a device for examining samples (1) in a liquid (5), comprising a movable shaft (2), to which the sample (1) is fastened, and a cuvette (4), wherein the device further comprises a bath (3), which surrounds the movable shaft (2), and wherein the bath (3) is fillable with the liquid (5), the movable shaft (2) is configured to receive the sample (1) at the upper side (24) thereof, the movable shaft (2) reaches into the cuvette (4) from below, wherein said cuvette is open at least toward the bottom and configured to be immersed into the liquid (5) in the bath (3) with the underside thereof, and, moreover, means are provided to generate a pressure difference between the interior of the cuvette (4) and the region outside of the cuvette (4) such that the fill level (21) of the liquid (5) in the cuvette (4) is adjustable. Moreover, the invention relates to a method for examining samples (1) in a liquid (5).

Abstract: Object of the invention is a process for depleting host cells from a xenograft of human cells on a murine host characterized in a) fragmenting the xenograft into a sample comprising a single cell suspension b) subjecting the sample to antibodies specific for a murine CD9 epitope coupled to a detection means c) depleting the cell suspension from cells bound by the CD9-antibodies using the detection means d) collecting the cells not bound by the CD9-antibodies as target cells.

Abstract: The present invention provides the in-vitro use of at least one in-vivo-target antigen of Aspergillus fumigatus for selective activation, detection and/or analysis of Aspergillus fumigatus specific CD4+ T cells in a sample comprising cells, wherein said at least one in-vivo-target antigen reveals an immune reactivity characterized by i) the in vivo existence of antigen-specific T cells comprising more than 60% memory T cells and ii) said antigen-specific T cells further comprise T cells able to produce IFN-gamma upon stimulation at a frequency between 15% and 80% and/or IL17 upon stimulation at a frequency between 5% and 30%. Said at least one in-vivo-target antigen may be selected from the group consisting of antigens Scw4, Pst1, Shm2, GliT and TpiA or fragments thereof. Also provided are a method, a composition, and a kit thereof.

Abstract: Lipophilic oligonucleotide comprising a phosphate glycerol unit containing at least one aliphatic unsaturated carbon bond according to formula (I), with Oligonucleotide an unmodified or modified nucleic acid of 2-1000 nucleotides in length R=a bond or a linker unit Y?OH, SH or NHR3 X and Z=independently O, S or NR3 R3=hydrogen or branched or unbranched and/or substituted or unsubstituted alkyl, aryl and/or alkyl aryl residue with 10 to 30 carbon atoms R1, R2 branched or unbranched and/or substituted or unsubstituted alkyl, aryl and/or alkylaryl residue with 10 to 30 carbon atoms, with the provisio that at least one of the residues R1 or R2 comprises at least one aliphatic carbon-carbon double bond Use of lipophilic oligonucleotide according to Formula I for drug discovery or for transfection of cells.

Abstract: The invention is directed to a homogenization device for cell suspensions, comprising a first rotating magnet; a shaft on which a propeller mixer is attached which rotates around the longitudinal axis of the shaft and is movable in lateral direction of the axis of the shaft; the propeller mixer being provided with at least two propeller blades of which at least one is provided with a second magnet; wherein the propeller mixer is rotated by magnetic interaction of the second magnet with the first rotating magnet.

Abstract: The invention is related to a device for suspending particles in a fluid, wherein the mixing device includes a first magnet (1) rotating around a longitudinal axis (2), a mixing rod (4) attached to a mount (6), the mount including a second magnet (3), wherein the mount (6) moves in a substantially orthogonal motion to the longitudinal axis of the mixing rod (4) by the interaction of the rotating first magnet with the second magnet (3).

Abstract: The invention relates to a process for generation of genetically modified stem cells comprising the steps a) providing a cell sample in suspension comprising stem cells in a centrifugation chamber comprising a base plate and cover plate connected by a cylinder b) adjusting the volumetric concentration of stem cells in the cell sample to at least 1×105 stem cells per mL cell sample by centrifugation c) introducing viral and/or non-viral vectors to the centrifugation chamber for genetically modifying the stem cells d) adjusting the spatial concentration of stem cells in the centrifugation chamber by rotating the centrifugation chamber at a speed where the cell sample is located at the outermost 35% of the radius of the base plate of the centrifugation chamber, thereby inducing gene modification of the stem cells.

Abstract: The invention relates to a cell containing a gene encoding a conditional transgenic surface marker that is detectable upon expression on the surface of the cell, wherein the gene encoding a conditional transgenic surface marker comprises: (i) a promoter, operably linked to (ii) a first transcription sequence, and (iii) a second transcription sequence encoding the surface marker, whereby the first transcription sequence prevents the transcription of the second transcription sequence, whereby the first transcription sequence is conditionally removable such that the second transcription sequence is transcribable, and whereby the surface marker renders the cell sortable through the detection of the conditional transgenic surface marker. Furthermore, the invention relates to a construct for generating such a cell, and to a method for separating such a cell from a population of cells.

Abstract: Polypeptide with an amino acid sequence according to SEQ ID No. 1 or a variant in which up to 10% of the amino acids have been altered by insertions, deletions or substitution.

Abstract: The present invention provides the use of the cell surface antigen CD51 as a negative selection marker for neuronal cells and a method for enrichment, isolation and/or detection of neuronal cells comprising the steps a) contacting a sample containing neuronal cells with an antigen-binding fragment specific for the CD51 antigen coupled to a solid phase, thereby labeling the CD51 positive cells of said sample and b) isolating the non-labeled cells of said sample.

Abstract: A heating device for single cylindrical laboratory vessels (e.g., laboratory test tubes), the heating device including a clamp-like element using a force-fit to encompass at least a part of each cylindrical laboratory vessel, one or more electrical resistance heating circuits located at the interior of the clamp-like element, and grab handles to open and close the clamp-like element, thereby to insert or release the cylindrical laboratory vessel from the heating device.

Abstract: The invention is directed to a centrifuge chamber comprising a cylinder having a base plate and a cover plate, a rotational axis with at least one port for input and/or output of liquids, at least one port for input of gases and at least one layer for cell culturing, wherein the layer for cell culturing comprises a gas-permeable membrane on which cells can be cultured and wherein the at least one port for input and/or output of gases is connected to the gas-permeable membrane.

Abstract: The present invention relates to novel conjugate complexes for immunoassays as well as kits comprising these conjugate complexes, methods of producing these complexes, and methods of detecting an analyte by use of these complexes. The conjugate complexes of the invention comprise one or more non-nucleic acid receptors capable of specifically binding an analyte, one or more nucleic acid markers comprising a predetermined nucleotide sequence, one or more first linker molecules capable of specifically binding the non-nucleic acid receptor and the nucleic acid marker, and one or more second linker molecules capable of specifically binding the first linker molecules.

Abstract: A process for preparing human relaxin-2 having the following amino acid sequence: A chain: (SEQ?ID?NO:?1) pGlu-Leu-Tyr-Ser-Ala-Leu-Ala-Asn-Lys-Cys-Cys-His- Val-Gly-Cys-Thr-Lys-Arg-Ser-Leu-Ala-Arg-Phe-Cys B chain: (SEQ?ID?NO:?2) Asp-Ser-Trp-Met-Glu-Glu-Val-Ile-Lys-Leu-Cys-Gly- Arg-Glu-Leu-Val-Arg-Ala-Gln-Ile-Ala-Ile-Cys-Gly- Met-Ser-Thr-Trp-Ser; comprising the following steps: providing the amino acids necessary for the synthesis of the A and B chains with usual protective groups, wherein the cysteines are employed as trityl-protected amino acids (L-Cys(Trt)-OH); effecting a chromatographic purification of the individual chains A and B after the solid state synthesis; followed by the simultaneous folding and combination of the individual chains A and B in ammonium hydrogencarbonate buffer at pH 7.9 to 8.4; and subsequent purification of the relaxin-2 formed.

Abstract: The invention relates to a cell modification device, comprising a centrifugation chamber with at least one cell modifying surface with a normal vector having an angle of 135-45° to the rotational axis of the centrifugation chamber, wherein the centrifugation chamber comprises at least one input/output port and the cells to be modified are immobilized at the cell modifying surfaces by the rotation of the centrifugation chamber at 2 to 2000 g.

Abstract: The invention relates to a laser assembly (100) having a laser (L) for generating primary laser pulses (1), beam splitting optics (15) for splitting a primary laser pulse into a plurality of temporally staggered sub-pulses, and having focusing optics (17-19) for focusing the sub-pulses in or on an object (20) so that every sub-pulse is focused in a separate focus volume (F). The invention is characterized in that the mutual spatial and/or temporal relationship of the focus volumes (F) of the sub-pulses originating from a common primary laser pulse is variably adjustable. The invention also relates to a corresponding method.

Abstract: The invention relates to a centrifuge for separating a sample into at least two components, comprising a chamber for receiving a sample to be centrifuged. According to the invention, the centrifuge further comprises a means for controlling the progress of the sample separation is located at the chamber.

Abstract: A method and associated device for enrichment of Neél-magnetic particles from a dispersion of Brown-magnetic particles and Neél-magnetic particles. The device and method use ferromagnetic separation particles having a mean diameter of 100 to 250 ?m located in a alternating magnetic field. The ferromagnetic separation particles have a magnetically and chemically inert coating.

Abstract: The invention relates to a centrifuge for separating a sample into at least two components, comprising a chamber for receiving a sample to be centrifuged. According to the invention, the centrifuge further comprises a means for controlling the progress of the sample separation is located at the chamber.

Abstract: The invention relates to a system, comprising: a) a sample processing unit, comprising an input port and an output port coupled to a rotating container having at least one sample chamber, the sample processing unit configured provide a first processing step to a sample or to rotate the container so as to apply a centrifugal force to a sample deposited in the chamber and separate at least a first component and a second component of the deposited sample; and b) a sample separation unit coupled to the output port of the sample processing unit, the cell separation unit comprising separation column holder (42), a pump (64) and a plurality of valves (1-11) configured to at least partially control fluid flow through a fluid circuitry and a separation column (40) positioned in the holder, the separation column configured to separate labeled and unlabeled components of sample flowed through the column.